Dividends Inside 
Eli Lilly and Company
LLY
$1,213.91 (+ $22.17 + 1.86%)
Last updated: 2026-07-04 00:20 UTC
Eli Lilly and Company trades under ticker LLY on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US5324571083, CUSIP 532457108.
About the Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Headquartered in Indianapolis, Indiana, the company focuses on therapies addressing diabetes, oncology, immunology, neuroscience, and cardiometabolic conditions. Its portfolio includes medicines for chronic metabolic diseases, cancer treatments aimed at specific tumor types, and immunology drugs targeting inflammatory and autoimmune disorders. Eli Lilly and Company serves healthcare systems, hospitals, and pharmacies worldwide, with a strong presence in major markets such as the United States, Europe, China, and Japan. The company operates across the full pharmaceutical value chain, from research and clinical development to large-scale manufacturing and global distribution. Through its focus on innovative, science-driven therapies for complex diseases, Eli Lilly and Company plays a significant role in the healthcare sector, supporting physicians and patients with branded medicines that are integrated into standard treatment protocols across multiple therapeutic areas.
Price History
Latest News for LLY
What Kroger (KR)'s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
Kroger recently expanded its offerings by rolling out Cold Case Ice Cream across more than 1,000 banner stores and, earlier this month, its pharmacies began offering Eli Lilly’s Zepbound KwikPen weight-management medication with access to various support and savings programs, alongside affirming a quarterly dividend of US$0.35 per share payable on June 1, 2026. Together, these moves highlight Kroger’s push to pair premium, differentiated grocery products with enhanced healthcare and pharmacy...
Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains.
Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.
Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF
After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.
Regional Bank Stock Up 33% as $3.7 Million Exit Tells a Different Story
First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses.
Top Analyst Reports for Eli Lilly, RTX & Abbott
Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising competition risks.
With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize
Half of every dollar invested in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) rides on just two companies pulling in opposite directions in 2026. With a 0.38% expense ratio, nearly $1.1 billion in net assets, and a 20-year track record dating to May 2006, it offers income-oriented and sector investors a focused vehicle for pharmaceutical exposure. Focused ... With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize